1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249. 2 Lu C,Rong D,Zhang B,et al.Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma:challenges and opportunities[J].Mol Cancer,2019,18(1):130. 3 王兴东,雷洁琼,李正果,等.槐耳颗粒治疗原发性肝癌的研究进展[J].甘肃医药,2021,4:297-298. 4 Zhou J,Sun H,Wang Z,et al.Guidelines for the diagnosis and treatment of hepatocellular carcinoma(2019 Edition)[J].Liver Cancer,2020,9(6):682-720. 5 Liu X,Liu L,Chen K,et al.Huaier shows anti-cancer activities by inhibition of cell growth,migration and energy metabolism in lung cancer through PI3K/AKT/HIF-1α pathway[J].J Cell Mol Med,2021,25(4):2228-2237. 6 Hsieh YT,Tu HF,Yang MH,et al.Mitochondrial genome regulator TFAM modulates head and neck tumorigenesis through activation of intracellular metabolic reprogramming and oncogenic effectors[J].Cell Death Dis,2020,12(11):961. 7 Feng RM,Zong YN,Cao SM,et al.Current cancer situation in China:good or bad news from the 2018 Global Cancer Statistics?[J].Cancer Commun(Lond),2019,39(1):22. 8 Larsson NG,Wang J,Wilhelmsson H,et al.Mitochondrial transcription factor A is necessary for mtDNA maintenance and embryogenesis in mice[J].Nat Genet,1998,18(3):231-236. 9 Bonawitz ND,Clayton DA,Shadel GS.Initiation and beyond:multiple functions of the human mitochondrial transcription machinery[J].Mol Cell,2006,24(6):813-825. 10 Takamatsu C,Umeda S,Ohsato T,et al.Regulation of mitochondrial D-loops by transcription factor A and single-stranded DNA-binding protein[J].EMBO Rep,2002,3(5):451-456. 11 Zuo Y,Qu C,Tian Y,et al.The HIF-1/SNHG1/miR-199a-3p/TFAM axis explains tumor angiogenesis and metastasis under hypoxic conditions in breast cancer[J].Biofactors,2021,47(3):444-460. 12 Zhao M,Wang Y,Li L,et al.Mitochondrial ROS promote mitochondrial dysfunction and inflammation in ischemic acute kidney injury by disrupting TFAM-mediated mtDNA maintenance[J].Theranostics,2021,11(4):1845-1863. 13 Zhu Y,Xu J,Hu W,et al.TFAM depletion overcomes hepatocellular carcinoma resistance to doxorubicin and sorafenib through AMPK activation and mitochondrial dysfunction[J].Gene,2020,753:144807. 14 谢海娟,王毓兴,张丽君,等.槐耳浸膏通过调控ROS抑制结直肠癌细胞MMP-9表达及侵袭能力的研究[J].中国中西医结合消化杂志,2021,29(5):6. 15 Thorpe LM,Yuzugullu H,Zhao JJ.PI3K in cancer:divergent roles of isoforms,modes of activation and therapeutic targeting[J].Nat Rev Cancer,2015,15(1):7-24. 16 Alessi DR,James SR,Downes CP,et al.Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha[J].Curr Biol,1997,7(4):261-269. 17 Fruman DA,Chiu HY,Hopkins BD,et al.The PI3K Pathway in Human Disease[J].Cell,2017,170(4):605-635. 18 Zamor PJ,Lemos AS,Russo MW.Viral hepatitis and hepatocellular carcinoma:etiology and management[J].J Gastrointest Oncol,2017,8(2):229-242. |